← Back to Search

Glucagon Response Study for Non-alcoholic Fatty Liver Disease

Phase 1 & 2
Recruiting
Research Sponsored by Adrian Vella
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 240 minutes of study
Awards & highlights
No Placebo-Only Group

Summary

This trial is examining whether or not glucagon resistance is caused by obesity, hepatic steatosis, or a combination of the two in people with and without type 2 diabetes.

Who is the study for?
This trial is for adults with obesity, Type 2 Diabetes, or Non-alcoholic Fatty Liver Disease who can consent to participate. It's not suitable for those with a history of certain abdominal surgeries, MRI contraindications like metal implants or claustrophobia, severe anemia (low hematocrit), abnormal thyroid levels (TSH), active illness/malignancy, significant vascular disease symptoms, or high alcohol consumption.
What is being tested?
The study investigates how glucagon—a hormone that affects blood sugar—interacts with liver metabolism in people who are lean and obese and may have Type 2 Diabetes. The focus is on understanding glucagon's role in breaking down amino acids and its relationship with liver fat content.
What are the potential side effects?
While the specific side effects aren't listed here, studies involving hormones like glucagon could potentially affect blood sugar levels and cause reactions at the injection site if applicable.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~240 minutes of study
This trial's timeline: 3 weeks for screening, Varies for treatment, and 240 minutes of study for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of Amino acid catabolism in the presence / absence of glucagon
Secondary study objectives
Effect of Diabetes on amino-acid catabolism

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Obese AdultsExperimental Treatment1 Intervention
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Group II: Healthy AdultsExperimental Treatment1 Intervention
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Group III: Adults with Type 2 DiabetesExperimental Treatment1 Intervention
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Adrian VellaLead Sponsor
8 Previous Clinical Trials
149 Total Patients Enrolled

Media Library

Glucagon response study Clinical Trial Eligibility Overview. Trial Name: NCT05500586 — Phase 1 & 2
Obesity Research Study Groups: Adults with Type 2 Diabetes, Healthy Adults, Obese Adults
Obesity Clinical Trial 2023: Glucagon response study Highlights & Side Effects. Trial Name: NCT05500586 — Phase 1 & 2
Glucagon response study 2023 Treatment Timeline for Medical Study. Trial Name: NCT05500586 — Phase 1 & 2
~17 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top